atezolizumab + bevacizumab + NKT2152

Atezolizumab + bevacizumab + NKT2152 is an investigational combination therapy under clinical evaluation for advanced clear cell renal cell carcinoma and potentially other solid tumors. - **Atezolizumab** is a monoclonal antibody checkpoint inhibitor targeting PD-L1, blocking the interaction between PD-L1 and its receptors to enhance immune-mediated tumor cell killing. - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), reducing angiogenesis and thereby limiting tumor blood supply. - **NKT2152** is a novel, potent, selective, orally available small molecule designed to inhibit hypoxia-inducible factor 2-alpha (HIF2α), a central oncogenic driver in clear cell renal cell carcinoma, by preventing HIF2α and HIF1β heterodimerization and transcription of hypoxia-driven and pro-angiogenic gene networks. The combination aims to simultaneously inhibit tumor-driven immune escape (via PD-L1 blockade), tumor angiogenesis (via VEGF-A inhibition), and oncogenic hypoxia signaling (via HIF2α inhibition).

Other names

atezolizumabbevacizumab